Barak V, Carlin D, Sulkes A, Treves A, Biran S
Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.
Isr J Med Sci. 1988 Sep-Oct;24(9-10):623-7.
Serum levels of the breast cancer-associated tumor marker CA15-3 were evaluated in three patient groups: breast, colorectal and ovarian cancer and in healthy subjects. Of 51 blood samples obtained from 31 patients with metastatic breast cancer (Stage IV disease), 98% had marker levels greater than 30 u/ml and 86% had levels greater than 50 u/ml. In contrast, of 49 samples from 42 patients with Stage I-II disease, 45% had levels greater than 30 u/ml but only 6% had levels greater than 50 u/ml (mean 29.5 +/- 18 u/ml). The mean level of the CA15-3 antigen in patients with Stage IV breast cancer and responding to therapy was 79.8 +/- 27 u/ml, while the mean level in patients not responding to therapy was 134 +/- 66 u/ml (P less than 0.02). The mean serial changes in CA15-3 levels for those responding to therapy was -28.4% while the mean change for those not responding to therapy was +44%. The mean marker level for 26 patients with colorectal carcinoma was 29.8 +/- 29 u/ml; 23% of these patients had levels greater than 30 u/ml and 7% had levels greater than 50 u/ml. No substantial difference was seen in those with active compared with nonactive colorectal carcinoma. The mean marker level for 14 patients with active ovarian carcinoma was 83 +/- 62 u/ml. Of these patients, 78% had CA15-3 levels greater than 30 u/ml and 50% had levels greater than 50 u/ml. All healthy subjects (n = 22) had marker levels less than 30 u/ml. We compared CA15-3 and CEA blood levels in the same patient population; 86% of patients with metastatic breast cancer (Stage IV disease) had CA15-3 levels greater than 50 u/ml while only 72% of these patients had CEA levels greater than 5 ng/ml. These findings suggest that the CA15-3 assay reflects the clinical course of patients with advanced breast cancer and may be superior to CEA as a monitor of therapeutic efficacy.
在三组患者中评估了乳腺癌相关肿瘤标志物CA15 - 3的血清水平：乳腺癌、结直肠癌和卵巢癌患者组以及健康受试者。从31例转移性乳腺癌（IV期疾病）患者获取的51份血样中，98%的患者标志物水平高于30 u/ml，86%的患者水平高于50 u/ml。相比之下，从42例I - II期疾病患者获取的49份样本中，45%的患者水平高于30 u/ml，但只有6%的患者水平高于50 u/ml（均值29.5 +/- 18 u/ml）。IV期乳腺癌且对治疗有反应的患者中CA15 - 3抗原的平均水平为79.8 +/- 27 u/ml，而对治疗无反应的患者平均水平为134 +/- 66 u/ml（P小于0.02）。对治疗有反应的患者CA15 - 3水平的平均系列变化为 - 28.4%，而对治疗无反应的患者平均变化为 + 44%。26例结直肠癌患者的标志物平均水平为29.8 +/- 29 u/ml；这些患者中23%的水平高于30 u/ml，7%的水平高于50 u/ml。活动期与非活动期结直肠癌患者之间未见实质性差异。14例活动期卵巢癌患者的标志物平均水平为83 +/- 62 u/ml。在这些患者中，78%的患者CA15 - l水平高于30 u/ml，50%的患者水平高于50 u/ml所有健康受试者（n = 22）的标志物水平均低于30 u/ml。我们在同一患者群体中比较了CA15 - 3和CEA的血水平；86%的转移性乳腺癌（IV期疾病）患者CA15 - 3水平高于50 u/ml，而这些患者中只有72%的CEA水平高于5 ng/ml。这些发现表明，CA15 - 3检测反映了晚期乳腺癌患者的临床病程，并且作为治疗疗效的监测指标可能优于CEA。
